MarketPulse

VK2735

4 articles
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Viking Therapeutics Advances Weight-Loss Candidate Into Late-Stage Trials

Viking Therapeutics advances obesity drug VK2735 into Phase 3 trials after positive interim results, positioning itself in the competitive weight-loss pharmaceutical market.
LLYNVOVKTXbiotechweight loss drugs
BenzingaBenzinga··Vandana Singh

Viking Therapeutics Climbs on Competitive Positioning in Obesity Drug Race

Viking Therapeutics surged 10.91% after Novo Nordisk's obesity drug failed against Eli Lilly's competitor. Viking's dual injectable/oral candidate VK2735 offers differentiation entering Phase 3 trials.
LLYNVORHHBYVKTXPhase 3 trialsweight loss
The Motley FoolThe Motley Fool··Adria Cimino

Viking Therapeutics Positioned for Market Expansion as Obesity Drug Sector Scales

Viking Therapeutics poised for growth as obesity drug market expands to $100 billion by decade's end. VK2735's Phase 3 success could establish the company as a key competitor.
LLYNVOVKTXbiotechPhase 3 trial
The Motley FoolThe Motley Fool··Adria Cimino

Viking Therapeutics Advances Obesity Treatment Pipeline Ahead of 2026 Trial Milestones

Viking Therapeutics advances obesity drug VK2735 through phase 3 trials, expecting 2026 trial data. Dual GIP/GLP-1 agonist targets $100B+ market opportunity.
LLYNVOVKTXbiotechclinical trials